Tilray Brands (NASDAQ:TLRY) announced an expansion of its medical cannabis portfolio in Australia, despite a challenging market environment.
The expansion includes new products under its Redecan and Good Supply brands, aimed at enhancing treatment options for healthcare professionals and patients.
This initiative underscores Tilray’s commitment to the Australian market, a key growth area, according to Rajnish Ohri, President of International at Tilray Brands. The expanded portfolio will offer medical cannabis flower, extracts, vapes, and pastilles, enhancing access to high-potency, patient-focused solutions.
While the broader market is down, with the Materials sector down 2.18%, Tilray’s stock movement appears more influenced by general market trends than by company-specific issues.
Technical Analysis
The stock is trading 11.3% below its 20-day simple moving average (SMA) and 30% below its 100-day SMA, indicating a bearish trend in the short- to medium-term. Over the past 12 months, shares have increased …
This post was originally published here
